179 related articles for article (PubMed ID: 30697077)
1. Clinicopathological and prognostic significance of
Wu X; Yao X; Cao Q; Wu Z; Wang Z; Liu F; Shen L
Cancer Manag Res; 2019; 11():857-864. PubMed ID: 30697077
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of possible role of cadherin gene methylation in evolution and prognosis of hepatocellular carcinoma with a PRISMA guideline.
Zhu C; Feng X; Ye G; Huang T
Medicine (Baltimore); 2017 Apr; 96(16):e6650. PubMed ID: 28422868
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Significance of NEK2 in Hepatocellular Carcinoma: Evidence from a Meta-Analysis and Retrospective Cohort Study.
Cheng Y; Chen X; Ye L; Zhang Y; Liang J; Liu W; Zhou B; Zheng S; Huang Y; Chen G; Deng Y; Zhang Q; Yang Y
Cell Physiol Biochem; 2018; 51(6):2746-2759. PubMed ID: 30562736
[TBL] [Abstract][Full Text] [Related]
4. The clinicopathological significance of CDH1 in gastric cancer: a meta-analysis and systematic review.
Zeng W; Zhu J; Shan L; Han Z; Aerxiding P; Quhai A; Zeng F; Wang Z; Li H
Drug Des Devel Ther; 2015; 9():2149-57. PubMed ID: 25926721
[TBL] [Abstract][Full Text] [Related]
5. The association, clinicopathological significance, and diagnostic value of
Shen Z; Zhou C; Li J; Deng H; Li Q; Wang J
Onco Targets Ther; 2016; 9():6763-6773. PubMed ID: 27826202
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance of RUNX3 gene hypermethylation in hepatocellular carcinoma.
Yang Y; Ye Z; Zou Z; Xiao G; Luo G; Yang H
Tumour Biol; 2014 Oct; 35(10):10333-40. PubMed ID: 25037468
[TBL] [Abstract][Full Text] [Related]
7. The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review.
Zhang L; Han J; Wu H; Liang X; Zhang J; Li J; Xie L; Xie Y; Sheng X; Yu J
PLoS One; 2014; 9(10):e110626. PubMed ID: 25356587
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological significance and potential drug targeting of CDH1 in lung cancer: a meta-analysis and literature review.
Yu Q; Guo Q; Chen L; Liu S
Drug Des Devel Ther; 2015; 9():2171-8. PubMed ID: 25931811
[TBL] [Abstract][Full Text] [Related]
10. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.
Wen G; Wang H; Zhong Z
Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221
[TBL] [Abstract][Full Text] [Related]
11. Identification of RASSF1A promoter hypermethylation as a biomarker for hepatocellular carcinoma.
Xu G; Zhou X; Xing J; Xiao Y; Jin B; Sun L; Yang H; Du S; Xu H; Mao Y
Cancer Cell Int; 2020 Nov; 20(1):547. PubMed ID: 33292241
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic and prognostic value of
Sun Z; Liu J; Jing H; Dong SX; Wu J
Oncotarget; 2017 Oct; 8(51):89142-89148. PubMed ID: 29179506
[TBL] [Abstract][Full Text] [Related]
13. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
Su Y; Wang X; Li J; Xu J; Xu L
Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis.
Luo Y; Ren F; Liu Y; Shi Z; Tan Z; Xiong H; Dang Y; Chen G
Int J Clin Exp Med; 2015; 8(7):10235-47. PubMed ID: 26379815
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of E-cadherin expression in hepatocellular carcinoma: a meta-analysis.
Chen J; Zhao J; Ma R; Lin H; Liang X; Cai X
PLoS One; 2014; 9(8):e103952. PubMed ID: 25093414
[TBL] [Abstract][Full Text] [Related]
16. Association of genetic variants in and promoter hypermethylation of CDH1 with gastric cancer: a meta-analysis.
Jing H; Dai F; Zhao C; Yang J; Li L; Kota P; Mao L; Xiang K; Zheng C; Yang J
Medicine (Baltimore); 2014 Oct; 93(19):e107. PubMed ID: 25340495
[TBL] [Abstract][Full Text] [Related]
17. Role of CDH1 promoter methylation in colorectal carcinogenesis: a meta-analysis.
Li YX; Lu Y; Li CY; Yuan P; Lin SS
DNA Cell Biol; 2014 Jul; 33(7):455-62. PubMed ID: 24684676
[TBL] [Abstract][Full Text] [Related]
18. Effects of E-cadherin (CDH1) gene promoter polymorphisms on the risk and clinicopathological development of hepatocellular carcinoma.
Chien MH; Yeh KT; Li YC; Hsieh YH; Lin CH; Weng MS; Kuo WH; Yang SF
J Surg Oncol; 2011 Sep; 104(3):299-304. PubMed ID: 21462191
[TBL] [Abstract][Full Text] [Related]
19. The association of PTEN hypermethylation and breast cancer: a meta-analysis.
Luo S; Chen J; Mo X
Onco Targets Ther; 2016; 9():5643-50. PubMed ID: 27672335
[TBL] [Abstract][Full Text] [Related]
20. Association of RASSF1A hypermethylation with risk of HBV/HCV-induced hepatocellular carcinoma: A meta-analysis.
Peng JL; Wu JZ; Li GJ; Wu JL; Xi YM; Li XQ; Wang L
Pathol Res Pract; 2020 Oct; 216(10):153099. PubMed ID: 32853942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
